Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers

Published:2020-03 Issue: Volume:128 Page:107-118
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Paci Angelo,Desnoyer Aude,Delahousse Julia,Blondel Louis,Maritaz Christophe,Chaput Nathalie,Mir Olivier,Broutin Sophie

Funder

Amgen

Astra-Zeneca

Bayer

Blueprint Medicines

Bristol Myers-Squibb

Eli-Lilly

Incyte

Ipsen Biopharmaceuticals

Lundbeck

MSD

Novartis

Pfizer

Roche

Servier

Vifor Pharma

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference72 articles.

1. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics;Golay;mAbs,2013

2. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma;Berinstein;Ann Oncol,1998

3. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study;Igarashi;Ann Oncol,2002

4. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma;Tobinai;Ann Oncol,2004

5. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response;Jäger;Haematologica,2012

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia;Cellular and Molecular Life Sciences;2024-08-28

2. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

3. In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors;Biomolecules;2024-05-18

4. Single-hit genome editing in B cells to redirect their specificity toward tumor antigens;2024-05-06

5. Half‐life extension of single‐domain antibody–drug conjugates by albumin binding moiety enhances antitumor efficacy;MedComm;2024-05